Maternal Hyperoxygenation in Congenital Heart Disease

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

A pilot study investigating the safety and feasibility of chronic maternal hyperoxygenation in the setting of fetal congenital heart disease

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Hospital for Sick Children

Criteria

Inclusion Criteria:

• Between 20-32 weeks gestation

• Diagnosis of fetus with a single ventricular ventricular heart

• Delivering at Mount Sinai Hospital

• Written informed consent

Exclusion Criteria:

• Opting for termination of pregnancy/ comfort care

• Normal exclusions for MRI (e.g. claustrophobia, cardiac pacemaker, etc.)

• Obesity

• Infections/ anemia

• Smoker

• Serious cardiorespiratory co-morbidities